In Reply to ‘Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy’

We agree with Duineveld et al1 that no definitive conclusions can be drawn from our retrospective study.2 Our primary goal was to describe the clinical use of eculizumab in patients with C3 glomerulopathy (C3G) in France. However, in the absence of prospective trials, our study, the largest to date, provides helpful information for clinicians, though obviously no hard recommendations can be made. The overall impression is that eculizumab is not cost-effective in most patients with C3G, but may be potentially helpful in some patients with rapidly progressive crescentic C3G, as previously suggested in small series.

https://ift.tt/2Nk83ck